Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Large-scale preparation method of H5N1 avian influenza virus-like particle vaccines

An avian influenza virus and virus-like technology, applied in the field of genetic engineering, can solve the problem that the production steps of virus-like particles are not suitable for large-scale production, and achieve the effect of good development and application prospects.

Inactive Publication Date: 2011-01-19
WUHAN UNIV
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, according to the implementation steps of the patent, it is not possible to start from influenza virus to produce virus-like particle vaccine products
The virus-like particle production steps involved in this patent are not suitable for the large-scale production of H5N1 avian influenza virus particles

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Large-scale preparation method of H5N1 avian influenza virus-like particle vaccines
  • Large-scale preparation method of H5N1 avian influenza virus-like particle vaccines
  • Large-scale preparation method of H5N1 avian influenza virus-like particle vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1H5

[0027] Construction and detection of embodiment 1H5N1 avian influenza virus virus-like particles (VLPs) vaccine

[0028] 1. Design and synthesis of primers

[0029] H5N1 Human Avian Influenza Virus Vaccine Strains Recommended by WHO

[0030] Hemagglutinin HA coding sequence (Genbank No.GQ454861), neuraminidase NA sequence (Genbank No.GQ454862) and matrix protein M sequence (Genbank No.GQ454867), respectively designed and synthesized three pairs of specific primers to amplify HA, NA and M1 genes respectively; designed a general primer for type A influenza virus for cDNA synthesis; each primer Synthesized by Shanghai Sangon Bioengineering Technology Co., Ltd.; the sequences and numbers of each primer are as follows:

[0031] 1) HA gene PCR amplification primers

[0032] Upstream primer P1 (SEQ ID NO.1)

[0033] 5′-TACCCGGGGCCAGCATGGAGAAAATAGT-3′

[0034] Downstream primer P2 (SEQ ID NO.2)

[0035] 5′-GGCTAGCTTAAATGCAAATTCTGC-3′

[0036] (The 5' end of the amplification ...

Embodiment 2H5

[0128] Example 2 Scale preparation and verification of H5N1 avian influenza virus virus-like particles (VLPs) vaccine

[0129] 1. Optimization of Sf9 insect cell culture conditions and large-scale cell suspension culture

[0130] 1) Optimum inoculum concentration optimization of recombinant baculovirus

[0131] Take well-growing Sf9 cells, digest them with 0.25% trypsin, inoculate them into 6-well plates, the cells form about 80% monolayer, and inoculate them at different dilutions of MOI=0.01, 0.1, 1, 3, 5 and 10 respectively The third-generation recombinant baculovirus, after adsorption for 1 hour, was replaced with fresh Grace's culture medium (2% fetal bovine serum), and cultured statically at 27°C. The virus fluid was harvested every day.

[0132] According to the method in step 8.2, measure the virus titration of each MOI infection dose after different propagation time, and determine the optimal infection dose and proliferation culture time of the recombinant baculov...

Embodiment 3H5

[0151] Functional detection of embodiment 3H5N1 avian influenza virus virus-like particles (VLPs) vaccine

[0152] In order to evaluate the safety and immune efficacy of the H5N1 avian influenza virus VLPs vaccine, the present invention uses BALB / c mice as animal models.

[0153] 1. Safety evaluation of H5N1 avian influenza virus VLPs vaccine

[0154] Get 20 healthy female BALB / c mice aged 5-6 weeks and divide them into 2 groups at random, 10 in each group. The mice in group A were intramuscularly injected with H5N1 avian influenza virus VLPs vaccine (10 μg / 100 μl per mouse), and the mice in group B Group mice were intramuscularly injected with 100 μl sterile PBS as a negative control.

[0155] The mice were observed for 21 days after injection, and the weight change was measured. On days 5, 7, 9, 14 and 21, blood was collected from the tail and the number of white blood cells was counted.

[0156] The results showed that there was no significant difference in body weight ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a large-scale preparation method of new H5N1 avian influenza virus-like particle vaccines, which sequentially comprises the following steps: (1) constructing and extracting the recombinant plasmid rbacmid / HANAM1; (2) transfecting the recombinant plasmid rbacmid / HANAM1 to Sf9 insect cells to revive the recombinant baculovirus, and assembling virus-like particles in the Sf9 cells; and (3) culturing and recombining the Sf9 cells in a large scale, and purifying the virus-infected particles and the virus-like particles. The method is suitable for large-scale preparation of human anti-highly pathogenic H5N1 avian influenza VLPs vaccines, and has the advantages of safety, high efficiency and good development and application prospects.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering and relates to a construction and large-scale preparation method of novel highly pathogenic H5N1 avian influenza virus-like particles (VLPs). technical background [0002] Influenza is an important infectious disease that endangers human health. The pathogen belongs to the Orthomyxoviridae family Influenza virus, which is divided into three types: A, B and C according to the antigenicity of the virus nucleoprotein. Influenza A Virus (IAV) is an enveloped RNA virus, and its genome consists of 8 segmented single-stranded negative-sense RNA segments. According to the antigenicity of hemagglutinin (HA) and neuraminidase (NA) on the surface of virions, influenza A viruses are divided into 16 different HA subtypes (H1-H16) and 9 different NA subtypes (N1 -N9). [0003] Influenza A virus has a wide host range and high variability, and is considered to be the greatest threat to future influ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/145C12N7/01A61P31/16C12R1/93
Inventor 朱丹丹陶攀璩骁潘兹书
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com